Skip to main content

Master of Public Health

The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus

AUTHORS

Giorgino F , Battelino T , Bergenstal RM , Forst T , Green JB , Mathieu C , Rodbard HW , Schnell O , Wilmot EG , . Journal of diabetes science and technology. 2023 11 8; (). 19322968231204584

ABSTRACT

Ultra-rapid-acting insulin analogs (URAA) are a further development and refinement of rapid-acting insulin analogs. Because of their adapted formulation, URAA provide an even faster pharmacokinetics and thus an accelerated onset of insulin action than conventional rapid-acting insulin analogs, allowing for a more physiologic delivery of exogenously applied insulin. Clinical trials have confirmed the superiority of URAA in controlling postprandial glucose excursions, with a safety profile that is comparable to the rapid-acting insulins. Consequently, many individuals with diabetes mellitus may benefit from URAA in terms of prandial glycemic control. Unfortunately, there are only few available recommendations from authoritative sources for use of URAA in clinical practice. Therefore, this expert consensus report aims to define populations of people with diabetes mellitus for whom URAA may be beneficial and to provide health care professionals with concrete, practical recommendations on how best to use URAA in this context.

Tags: